

## ON-GOING COMPLIANCE FORM FOR NOTICE OF MERGERS/RESTRUCTURING/TERMINATION/WITHDRAWAL OF AUTHORIZATION

**Note: This form may be used with immediate effect from 25 January 2018 and must be completed and submitted to the Commission together with the draft notice to investors (the "Draft Notice") relating to any proposed withdrawal of authorization of a collective investment scheme ("CIS") or proposed merger, restructuring and/or termination of a CIS for authorization by the Commission respectively pursuant to 11.4 or 11.5 of the Code on Unit Trusts and Mutual Funds (the "Code"). For the avoidance of doubt, any applicant who wishes to make an application received by the Commission after 14 February 2018 should use and complete this form.**

For the avoidance of doubt, if any share class or share classes under the same CIS is or are to be merged, restructured and/or terminated and there is/are Hong Kong investor(s) (including any insurance company(ies) which is/are issuer(s) of SFC-authorized ILAS linked to the performance of the CIS) in the absorbed CIS or terminated CIS, as applicable, this form shall also be completed and submitted to the Commission together with the Draft Notice for authorization by the Commission prior to its issuance. In the latter case, the term "Fund(s)" and "CIS" referred to in this form shall be construed as the relevant share class and share classes (as the case may be).

For any proposed withdrawal of authorization that does not involve any HK investors or investor(s) who is/are insurance company(ies) which is/are issuer(s) of SFC-authorized ILAS linked to the performance of the CIS, you are only required to fill in the below items (1), (3), (5), (7), (11), (25), (26) and (28) only.

For any proposed withdrawal of authorization of a CIS subsequent to approval of notice by the Commission relating to any merger, restructuring and/or termination of the CIS, you are not required to submit this form. The application letter for the withdrawal of authorization from the approved person should include the relevant confirmations <sup>Note 3</sup>.

	Details
<b>1. Proposed resolution (mergers/restructuring/termination/withdrawal of authorization)</b> <sup>Note 1</sup>	
<b>2. For mergers/restructuring/termination, conform with constitutive documents (Y/N)?</b> <ul style="list-style-type: none"> <li>• reference clauses</li> </ul>	
<b>3. Fund(s) affected</b> <sup>Note 1</sup> <ul style="list-style-type: none"> <li>• absorbing</li> <li>• absorbed</li> <li>• termination</li> <li>• withdrawal of authorization</li> </ul>	
<b>4. Latest fund size of each affected CIS /date</b> <sup>Note 1</sup>	
<b>5. To the management company's reasonable knowledge, is/are there any investor(s) which is/are insurance company(ies) which is/are issuer(s) of SFC-authorized ILAS linked to the</b>	



	Details
<b>performance of the Fund(s) (Y/N)?</b> <ul style="list-style-type: none"> <li><b>No. of HK investors of each affected CIS</b> <small>Note 2</small></li> </ul>	
<b>6. For mergers/restructuring, change in investment objectives, fee structure and other changes of the merged/reconstructed CIS</b> <small>Note 1</small>	
<b>7. Reasons for mergers/restructuring/termination/withdrawal of authorization</b> <small>Note 1</small>	
<b>8. No. of units/shares exchanged (conversion ratio)</b> <small>Note 1</small>	
<b>9. Alternatives to investors and their respective fees and charges</b> <small>Note 1</small>	
<b>10. EGM date</b> <small>Note 1</small> <b>if applicable</b>	
<b>11. Effective date of mergers/restructuring/termination/withdrawal of authorization</b> <small>Note 1</small>	
<b>12. Proposed notice period till</b> <small>Note 1</small> <ul style="list-style-type: none"> <li><b>EGM</b></li> <li><b>Effective date</b></li> </ul>	
<b>13. For termination, total expense ratio of each affected CIS</b> <small>Note 1</small> <ul style="list-style-type: none"> <li><b>date</b></li> <li><b>basis of calculation</b></li> </ul>	
<b>14.</b> <ul style="list-style-type: none"> <li><b>Who will bear the costs of merger/restructuring/withdrawal of authorization</b> <small>Note 1</small></li> <li><b>Amount of costs which will be borne by the fund and/or investors</b> <small>Note 1</small></li> </ul>	
<b>15. For mergers/restructuring/termination, the amount of unamortized preliminary expenses and treatment upon mergers/restructuring/termination</b> <small>Note 1</small> <b>(if any)</b>	
<b>16. Tax implications to HK investors</b> <small>Note 1</small>	
<b>17. For mergers/restructuring/termination, the documents available for inspection</b> <small>Note 1</small> <b>stated in notice (Y/N)?</b>	
<b>18. Prominent warning statement to the effect that “THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE”</b> <small>Note 1</small> <b>in notice (Y/N)?</b>	



	Details
<p><b>19. For merger/termination, statement to the effect that the absorbed fund/terminated fund is no longer allowed to be marketed to the public in Hong Kong and shall not accept subscription from new investors with effect from the date of the notice</b> <sup>Note 1</sup></p> <p><b>For withdrawal of authorization, statement to the effect that the fund is no longer allowed to be marketed to the public in Hong Kong</b> <sup>Note 1</sup></p>	
<p><b>20. Responsibility statement to the effect that “the directors/fund managers accept responsibility for the accuracy of the contents of the documents”</b> <sup>Note 1</sup> in notice (Y/N)?</p>	
<p><b>21. For mergers/restructuring/termination, trustee/custodian written consent attached (Y/N)?</b></p>	
<p><b>22. (Applicable only to overseas scheme(s) primarily regulated by overseas regulator) For mergers/restructuring/termination,</b></p> <ul style="list-style-type: none"> <li>• subject to home regulator’s approval (Y/N)?</li> <li>• home regulator’s approval obtained (Y/N)?</li> </ul>	
<p><b>23. Hong Kong contact details</b> <sup>Note 1</sup> stated (Y/N)?</p>	
<p><b>24. Chinese translation of notice submitted (Y/N)?</b></p>	
<p><b>25. Need to update offering documents (Y/N)?</b></p>	
<p><b>26. Withdrawal of authorization from approved person submitted (Y/N)?</b></p>	
<p><b>27. For withdrawal of authorization, any proposed changes in the operation of the CIS and the effects on existing investors</b> <sup>Note 1</sup></p>	
<p><b>28. Other issues (including any specific issues/considerations and/or circumstances for consideration by the Commission to process the application as a Complex Application)</b></p>	

Notes

- 1 *Items required to be disclosed in the notice. Apart from the above, a withdrawal of authorization notice should also disclose the status of the Fund(s) after withdrawal of authorization, including amongst others, that (i) the Fund(s) will no longer be regulated by the SFC and not available for public distribution in HK; (ii) product documentation previously issued to investors should be retained for personal use only and not for public circulation; (iii) a statement to the effect that the manager shall continue to manage the Fund(s) in accordance with the Fund(s)' constitutive documents despite the withdrawal of authorization or a statement that apart from the withdrawal of authorization, the manager confirms that there is no change in the operation of the Fund(s). Please note that the SFC may require additional disclosures and the contents of the notice will vary according to the circumstances.*
- 2 *If investor(s) of the CIS includes insurance company(ies) which is/are issuer(s) of SFC-authorized ILAS linked to the performance of the CIS, please make sure that you include those investor(s) who may be affected by their investment via such ILAS issuer(s) (if known). For the purposes of filing this form, the management company may regard such an ILAS issuer as ONE HK investor and should disclose this clearly in the form if it has no information concerning the end HK investors who are investors in the Fund(s) via such an ILAS.*
- 3 *Application is required to be made by the approved person to the SFC in writing seeking for withdrawal of authorization of the CIS. In such application letter, relevant information should be included, such as confirmation that there are no investors or assets in the fund. Please note that the SFC may require additional confirmations / information according to the circumstances.*